Pharma Group Backs Abortion Pill Maker in Supreme Court Clash (1)

A major pharmaceutical industry lobby is wading into a potential US Supreme Court battle over access to the abortion medication mifepristone, warning the justices that lower court restrictions invite litigation that could disrupt drug development.

In a brief filed with the high court Thursday, the Pharmaceutical Research and Manufacturers of America (PhRMA) argued that a lower court’s restrictions on mifepristone would upend the “settled regulatory scheme and the investments that hinge upon it” while inviting “boundless litigation to FDA drug approvals.”

“Should the decision below stand, FDA’s safety determinations will risk becoming mere precursors to litigation, rather than durable decisions ...